DK2187967T3 - Fremgangsmåde og sammensætninger til behandling af cancere - Google Patents

Fremgangsmåde og sammensætninger til behandling af cancere

Info

Publication number
DK2187967T3
DK2187967T3 DK08797814.4T DK08797814T DK2187967T3 DK 2187967 T3 DK2187967 T3 DK 2187967T3 DK 08797814 T DK08797814 T DK 08797814T DK 2187967 T3 DK2187967 T3 DK 2187967T3
Authority
DK
Denmark
Prior art keywords
compositions
methods
treating cancers
cancers
treating
Prior art date
Application number
DK08797814.4T
Other languages
English (en)
Inventor
Markus Warmuth
Christine Dierks
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Application granted granted Critical
Publication of DK2187967T3 publication Critical patent/DK2187967T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK08797814.4T 2007-08-16 2008-08-13 Fremgangsmåde og sammensætninger til behandling af cancere DK2187967T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95629507P 2007-08-16 2007-08-16
PCT/US2008/073049 WO2009026075A1 (en) 2007-08-16 2008-08-13 Methods and compositions for treating cancers

Publications (1)

Publication Number Publication Date
DK2187967T3 true DK2187967T3 (da) 2013-07-22

Family

ID=40210407

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08797814.4T DK2187967T3 (da) 2007-08-16 2008-08-13 Fremgangsmåde og sammensætninger til behandling af cancere

Country Status (16)

Country Link
US (3) US20100216828A1 (da)
EP (1) EP2187967B1 (da)
JP (1) JP2010536775A (da)
KR (1) KR20100056525A (da)
CN (1) CN101820915A (da)
AU (1) AU2008289255B2 (da)
BR (1) BRPI0815330A2 (da)
CA (1) CA2699988A1 (da)
DK (1) DK2187967T3 (da)
ES (1) ES2422285T3 (da)
HR (1) HRP20130642T1 (da)
MX (1) MX2010001813A (da)
PL (1) PL2187967T3 (da)
RU (1) RU2010109452A (da)
SI (1) SI2187967T1 (da)
WO (1) WO2009026075A1 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102105147B (zh) * 2008-07-24 2013-07-03 内尔维阿诺医学科学有限公司 包含aurora激酶抑制剂和抗肿瘤药的治疗组合
US20110039850A1 (en) * 2009-08-12 2011-02-17 Mhairi Copland Leukemia Treatment
MX2012004709A (es) * 2009-10-23 2012-05-23 Novartis Ag Metodo para el tratamiento de transtornos proliferativos y otras condiciones patologicas mediadas por la actividad de cinasa de bcr-abl, c-kit, ddr1, ddr2 o pdgf-r.
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN103768067A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
CN104262262B (zh) * 2014-08-29 2016-06-08 西安交通大学 一种N,6二苯基嘧啶-4-胺类Bcr-Abl抑制剂及其制备方法和应用
CN109744199A (zh) * 2017-11-08 2019-05-14 南京艾莫瑞生物科技有限公司 一种肿瘤细胞异种移植斑马鱼模型、其构建方法及应用
WO2018211007A1 (en) * 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
CN108721217B (zh) * 2018-08-21 2020-09-08 武汉轻工大学 抗肿瘤药物组合物及药物制剂和应用
WO2020198055A1 (en) * 2019-03-22 2020-10-01 Yale University Allosteric bcr-abl proteolysis targeting chimeric compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
WO2003088970A2 (en) 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004072266A2 (en) 2003-02-13 2004-08-26 Kalobios Inc. Antibody affinity engineering by serial epitope-guided complementarity replacement
KR101366414B1 (ko) 2004-09-02 2014-03-18 쿠리스 인코퍼레이션 헤지호그 신호전달에 대한 피리딜 억제제
US8633161B2 (en) * 2005-03-24 2014-01-21 The Ohio State University Research Foundation Therapeutic agents for the treatment of leukemia

Also Published As

Publication number Publication date
AU2008289255A1 (en) 2009-02-26
JP2010536775A (ja) 2010-12-02
CN101820915A (zh) 2010-09-01
SI2187967T1 (sl) 2013-07-31
AU2008289255B2 (en) 2012-02-02
MX2010001813A (es) 2010-03-10
ES2422285T3 (es) 2013-09-10
HRP20130642T1 (en) 2013-08-31
PL2187967T3 (pl) 2013-09-30
BRPI0815330A2 (pt) 2017-05-09
US20120165355A1 (en) 2012-06-28
WO2009026075A1 (en) 2009-02-26
KR20100056525A (ko) 2010-05-27
CA2699988A1 (en) 2009-02-26
EP2187967B1 (en) 2013-04-24
US20130210771A1 (en) 2013-08-15
RU2010109452A (ru) 2011-09-27
EP2187967A1 (en) 2010-05-26
US20100216828A1 (en) 2010-08-26

Similar Documents

Publication Publication Date Title
NO20200775A1 (no) Fremgangsmåter og sammensetninger for behandling av kreft
DK2155188T3 (da) Fremgangsmåder og sammensætninger til behandling af tilbagevendende kræft
DK2894165T5 (da) Fremgangsmåder og sammensætninger til behandling af komplementforbundne forstyrrelser
DK2323638T3 (da) Sammensætninger og fremgangsmåder til behandling af osteoartritis
DK2429574T3 (da) Sammensætninger og fremgangsmåder til behandling af hæmatologiske cancere der targeterer sirp-cd47-interaktionen
DK2187967T3 (da) Fremgangsmåde og sammensætninger til behandling af cancere
DK2365802T3 (da) Mikrokapsler af rapamycin og anvendelse til behandling af cancer
DK2203478T3 (da) Sammensætninger og fremgangsmåder til anvendelse af antistoffer mod sclerostin
DK2252342T3 (da) Indretninger og fremgangsmåder til behandling af skadet væv
DK2066339T3 (da) Sammensætninger og fremgangsmåder til forstærkning af immunreaktioner
DK2087002T3 (da) Sammensætninger og fremgangsmåder til binding af sphingosin-1-phosphat
DK2570467T3 (da) Sammensætninger af tetrafluorpropen og carbonhydrider
DK2187880T3 (da) Sammensætninger og fremgangsmåder til behandling af makuladegeneration
DK3263589T5 (da) Peptidsekvenser og sammensætninger
BRPI0809573A2 (pt) composição, e, método
DK2170827T3 (da) Indolin-2-oner og aza-indolin-2-oner
DK2340042T3 (da) Fremgangsmåder og præparater til behandling af cancer
DK2361090T3 (da) Sammensætninger til behandling af centralt medieret kvalme og opkastning
DK2865422T3 (da) Alpha-msh-derivater til behandling af fotodermatoser
DK2222314T3 (da) Anvendelser og midler til opnåelse af bronchorelaxation
DK3443957T3 (da) Forbindelser og sammensætninger til behandling af cancer
BRPI0814167A2 (pt) Composição, e, método
DK3263112T3 (da) Sammensætninger og fremgangsmåder til undertrykkelse af endometriproliferationer
DK2442832T3 (da) Sammensætninger og fremgangsmåder til behandling af dissemineret sclerose
BRPI0812932A2 (pt) Composições e métodos de tratar câncer